ARTICLE | Company News
Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up front. Tusk shareholders are eligible to receive €585 million ($686.8 million) in undisclosed milestones.
Roche will gain Tusk's mAbs against CD25, a component of the IL-2 receptor, which has the potential to aid cancer immunotherapy. ...